RecruitingPhase 1Phase 2NCT05333250

Modafinil to Improve Fatiguability

Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT


Sponsor

Ottawa Hospital Research Institute

Enrollment

40 participants

Start Date

Jan 22, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Modafinil and Placebo for people with cancer-related cognitive difficulties, cancer-related problem/condition, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGModafinil

Modafinil

OTHERPlacebo

Placebo


Locations(1)

The Ottawa Hospital

Ottawa, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05333250


Related Trials